Journal of Clinical Psychopharmacology · 2001 · 40 citations · 46 references
MedicinePharmacologyPsychiatryNeuropharmacologyPsychiatric PharmacotherapyPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapySchizophrenia PharmacotherapySchizophrenia Spectrum DisordersSerotonergic Pharmacology5-Hydroxytryptamine Receptor PharmacologyAdrenocorticotropic Hormone RegulationAdrenocorticotropic Hormone SecretionAntipsychotic ActionAtypical Antipsychotic TreatmentClozapine PharmacologyOlanzapine PharmacologyReceptors
In addition to dopamine, serotonin (5-hydroxytryptamine, 5-HT) has been reported to play an important role in schizophrenia. Besides blocking dopamine, atypical antipsychotics also block 5-HT receptors. The clinical efficacy of the atypical antipsychotic clozapine is associated with the 5-HT antagonistic action of the drug and a high serotonergic tone before treatment. The atypical antipsychotic olanzapine has a receptor-binding profile similar to that of clozapine. The present study investigated whether treatment with olanzapine blocks hormone release induced by the 5-HT2c agonist m-chlorophenylpiperazine (m-CPP) and, if so, whether this 5-HT antagonistic effect is related to treatment response. Eighteen male schizophrenic patients participated in this study. All patients were challenged with m-CPP (0.5 mg/kg orally) in a double-blind, randomized, placebo-controlled design after a drug-free period of at least 2 weeks. Adrenocorticotropic hormone (ACTH), cortisol, and prolactin plasma levels were measured every 30 minutes up to 210 minutes after challenge. Patients were treated for 6 weeks with 10 mg olanzapine daily in an open design, after which the challenge tests were repeated. Olanzapine significantly blocked m-CPP-induced ACTH, cortisol, and prolactin release, suggesting that it is a potent 5-HT2c antagonist in vivo. This 5-HT antagonistic effect of olanzapine was not significantly correlated with treatment response. Also, no significant correlation was found between m-CPP-induced hormone release before treatment and clinical response after treatment with olanzapine. These findings suggest that olanzapine is a potent 5-HT2c antagonist in vivo but that this is unrelated to its clinical efficacy in this nonrefractory sample of schizophrenic patients.
46
The Brief Psychiatric Rating Scale
John E. Overall, Donald R. Gorham · Psychological Reports · 1962 · 10.9K citations
Clozapine for the Treatment-Resistant Schizophrenic
John M. Kane · Archives of General Psychiatry · 1988 · 4.1K citations
Medicine, Pharmacology, Psychiatry +16
The Comprehensive Assessment of Symptoms and History (CASH)
Nancy C. Andreasen · Archives of General Psychiatry · 1992 · 1.3K citations
Medicine, Neurobiology, Psychiatry +17
THE BRIEF PSYCHIATRIC RATING SCALE
John E. Overall · Psychological Reports · 1962 · 1.1K citations